Healthcare Executive, 22 January 2021:

Sanjiv Navangul, M.D. & CEO of BSV (Bharat Serums & Vaccines Ltd.) believes the budget is likely to focus on a quick ‘recovery’ from pandemic lessons. He says, “The need of the hour for our industry is the availability and affordability of life-saving drugs for our billion-plus populace. The government’s vision for Atmanirbharta is based largely on the good work that authorities such as the DPCO will take up. The Union budget should address long-standing special incentives and subsidies to encourage indigenous drugs and API production in line with Atmanirbharta. There should be tax cuts on life-saving drugs to make them affordable. We must also provide full medical cover to proactively help indisposed and senior citizens. Grants to Indian companies that make novel drugs should be made available to speed up patents and inventions. Flexible pricing policies that can encourage upto 7% MRP increase year on year and giving 300 percent deduction for R&D expenses will be beneficial for the industry.”

Read more: https://medgatetoday.com/union-budget-2021-expectations-healthcare/

About BSV

BSV has been a pioneer in the development of blood components and therapeutic antibody products for infectious and non-infectious diseases. For over four decades, BSVL has focused on utilizing its scientific resources to develop several biological, biotechnology and pharmaceutical products to treat various types of diseases, contributing to preserve, protect and enhance the quality of life. We aim to be a leading biopharmaceutical company driven by people & science to set benchmarks in patient outcomes in Women’s Health, Critical Care & Emergency Medicine.

For more information, please contact:

Irawati Gowariker, BSV, Irawati.gowariker@bsvgroup.com